

Jacob A Sloane

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7194709/jacob-a-sloane-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47
papers

1,767
citations

19
h-index

42
g-index

50
ext. papers

2,075
ext. citations

6.3
avg, IF

4.4
L-index

#	Paper	IF	Citations
47	Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. <i>Journal of Cell Biology</i> , 2006 , 175, 209-15	7.3	208
46	Increased microglial activation and protein nitration in white matter of the aging monkey. <i>Neurobiology of Aging</i> , 1999 , 20, 395-405	5.6	178
45	Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. <i>Journal of Neuroscience</i> , 2007 , 27, 13033-41	6.6	170
44	Neuroinflammatory component of gray matter pathology in multiple sclerosis. <i>Annals of Neurology</i> , 2016 , 80, 776-790	9.4	114
43	The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS. <i>Journal of Neuroscience</i> , 2013 , 33, 1927-39	6.6	108
42	In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. <i>Brain</i> , 2017 , 140, 2912-2926	11.2	98
41	A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. <i>Brain</i> , 2015 , 138, 932-45	11.2	93
40	WAVE1 is required for oligodendrocyte morphogenesis and normal CNS myelination. <i>Journal of Neuroscience</i> , 2006 , 26, 5849-59	6.6	76
39	Astrocytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey. <i>Brain Research</i> , 2000 , 862, 1-10	3.7	73
38	A clear and present danger: endogenous ligands of Toll-like receptors. <i>NeuroMolecular Medicine</i> , 2010 , 12, 149-63	4.6	72
37	Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation. <i>Journal of Biological Chemistry</i> , 1999 , 274, 18777-84	5.4	70
36	Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. <i>Neuroscience Letters</i> , 1997 , 225, 73-6	3.3	61
35	Regulation of remyelination in multiple sclerosis. <i>FEBS Letters</i> , 2011 , 585, 3821-8	3.8	55
34	JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. <i>Annals of Neurology</i> , 2014 , 75, 925-34	9.4	39
33	COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 2790-2796	3.7	37
32	Myosin Va controls oligodendrocyte morphogenesis and myelination. <i>Journal of Neuroscience</i> , 2007 , 27, 11366-75	6.6	35
31	Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI. <i>Radiology</i> , 2019 , 291, 740-749	20.5	32

30	Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T. <i>Neurology</i> , 2015 , 85, 1702-9	6.5	30
29	Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1433-1444	5	25
28	The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T* mapping at 7T MRI. <i>NeuroImage: Clinical</i> , 2016 , 12, 879-886	5.3	19
27	Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate. <i>Journal of Neurology</i> , 2020 , 267, 125-131	5.5	18
26	WAVE1 and regulation of actin nucleation in myelination. <i>Neuroscientist</i> , 2007 , 13, 486-91	7.6	17
25	Changes in structural network are associated with cortical demyelination in early multiple sclerosis. <i>Human Brain Mapping</i> , 2018 , 39, 2133-2146	5.9	13
24	Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes. <i>Neurology and Therapy</i> , 2019 , 8, 109-119	4.6	12
23	Social-emotional aspects of quality of life in multiple sclerosis. <i>Psychology, Health and Medicine</i> , 2018 , 23, 411-423	2.1	12
22	Biotin supplementation in MS clinically valuable but can alter multiple blood test results. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 619-620	5	11
21	Profiles of cortical inflammation in multiple sclerosis by C-PBR28 MR-PET and 7 Tesla imaging. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1497-1509	5	11
20	Is the Relationship between Cortical and White Matter Pathologic Changes in Multiple Sclerosis Spatially Specific? A Multimodal 7-T and 3-T MR Imaging Study with Surface and Tract-based Analysis. <i>Radiology</i> , 2016 , 278, 524-35	20.5	10
19	Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients. <i>Journal of Neurology</i> , 2018 , 265, 2342-2345	5.5	10
18	7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. <i>Brain</i> , 2020 , 143, 2973-2987	11.2	10
17	Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. <i>Journal of Neurology</i> , 2016 , 263, 1511-7	5.5	10
16	Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice. <i>Journal of Neuroimaging</i> , 2020 , 30, 917-929	2.8	6
15	Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 674-683	5	5
14	Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression. <i>Brain Communications</i> , 2021 , 3, fcb134	4.5	5
13	No Evidence of Disease Activity in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 835-6	17.2	4

12	Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing. <i>International Journal of MS Care</i> , 2021 , 23, 26-30	2.3	3
11	CLICK-MS and MASTER-2 Phase IV Trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2021 , 11, 99-111	2.8	3
10	The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI. <i>Journal of Neurology</i> , 2021 , 268, 2473-2481	5.5	3
9	A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
8	PML-IRIS in an HIV-2-infected patient presenting as Bell's palsy. <i>Journal of NeuroVirology</i> , 2017 , 23, 789-792	5.9	2
7	Brainstem lesions are associated with sleep apnea in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320967955	2	2
6	Unilateral Relapsing Primary Angiitis of the CNS: An Entity Suggesting Differences in the Immune Response Between the Cerebral Hemispheres. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
5	Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 59, 103505	4	1
4	Challenges in the diagnosis and treatment of CNS demyelinating disorders in Zambia. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016 , 2, 2055217316657117	2	1
3	Quantitative 7-Tesla Imaging of Cortical Myelin Changes in Early Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021 , 12, 714820	4.1	0
2	045 Delayed-release dimethyl fumarate demonstrated no difference in clinical outcomes versus fingolimod in patients with relapsing-remitting multiple sclerosis: results from the real-world effect study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A19.1-A19	5.5	
1	Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments.. <i>Frontiers in Neurology</i> , 2022 , 13, 843081	4.1	